Spinal muscular atrophy is one of the most devastating neurological diseases of childhood. Affected infants and children suffer from often severe muscle weakness caused by degeneration of lower motor neurons in the spinal cord and brainstem. Identification of the causative genetic mutation in most cases has resulted in development of potential treatment strategies. To test these new drugs, clinically feasible outcomes are needed. Several different assessments, validated in spinal muscular atrophy or similar disorders, are being used by national and international research groups; however, their sensitivity to detect change is unknown. Acceptance of a few standardized, easily administered, and functionally meaningful outcomes, applicable to the phenotypic spectrum of spinal muscular atrophy, is needed. Consensus is imperative to facilitate collaboration and explore the ability of these measures to identify the therapeutic effect of disease-modifying agents. Following is an evidence-based review of available clinical outcome measures in spinal muscular atrophy.
Crawford TOSpinal muscular atrophies. In: Jones RH , De Vivo DC, Darras BT, eds. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Philadelphia, PA: Butterworth Heinemann;2003:145-166.
2.
Brzustowicz LM, Lehner T., Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3 . Nature . 1990;344:540-541.
3.
Munsat TL, Skerry L., Korf B., et al. Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q). Neurology. 1990;40:1831-1836.
4.
Feldkotter M. , Schwarzer V., Wirth R., Wienker TF, Wirth B.Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358-368.
5.
Burd L., Short SK, Martsolf JT, Nelson RAPrevalence of type I spinal muscular atrophy in North Dakota. Am J Med Genet. 1991;41:212-215.
6.
Zerres K., Rudnik-Schoneborn S., Forkert R., Wirth B.Genetic basis of adult-onset spinal muscular atrophy. Lancet . 1995; 346:1162.
7.
Ioos C., Leclair-Richard D., Mrad S., Barois A., Estournet-Mathiaud B.Respiratory capacity course in patients with infantile spinal muscular atrophy . Chest. 2004;126:831-837.
8.
Zerres K., Rudnik-Schoneborn S., Forrest E., Lusakowska A., Borkowska J., Hausmanowa-Petrusewicz I.A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients . J Neurol Sci. 1997;146:67-72.
9.
Crawford TOConcerns about the design of clinical trials for spinal muscular atrophy . Neuromuscul Disord. 2004;14: 456-460.
10.
Ignatius J.The natural history of severe spinal muscular atrophy-further evidence for clinical subtypes. Neuromuscul Disord. 1994;4:527-528.
11.
Oskoui M., Levy G., Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69: 1931-1936.
12.
Wang CH, Finkel RS, Bertini ES, et al, and the Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027-1049.
13.
Russman BS, Buncher CR, White M., Samaha FJ, Iannaccone STFunction changes in spinal muscular atrophy II and III. The DCN/SMA Group . Neurology. 1996;47:973-976.
14.
von Gontard A., Zerres K., Backes M., et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy . Neuromuscul Disord. 2002;12:130-136.
15.
Sumner CJTherapeutics development for spinal muscular atrophy. NeuroRx . 2006;3:235-245.
16.
WHO.International Classification of Functioning, Disability and Health. Final Draft. Geneva : World Health Organization; 2001 .
17.
Kaufmann P. , Muntoni F., and the International Coordinating Committee for SMA Subcommittee on SMA Clinical Trial Design.Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design . Neuromuscul Disord. 2007;17:499-505.
18.
Russman BS, Iannaccone ST, Samaha FJA phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol. 2003;60: 1601-1603.
19.
Piper MC, Pinnell LE, Darrah J., Maguire T., Byrne PJConstruction and validation of the Alberta Infant Motor Scale (AIMS) . Can J Public Health. 1992;83(suppl 2):S46-S50.
20.
Spittle AJ, Doyle LW, Boyd RNA systematic review of the clinimetric properties of neuromotor assessments for preterm infants during the first year of life. Dev Med Child Neurol. 2008;50:254-266.
21.
Klinge L., Straub V., Neudorf U., Voit T.Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics. 2005;36:6-11.
22.
Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk . Pediatrics. 2004;113: e448-e457.
23.
Cameron EC, Maehle V., Reid J.The effects of an early physical therapy intervention for very preterm, very low birth weight infants: a randomized controlled clinical trial. Pediatr Phys Ther. 2005;17:107-119.
24.
Bertini E., Burghes A., Bushby K., et al. 134th ENMC International Workshop: outcome measures and treatment of spinal muscular atrophy, 11-13 February 2005, Naarden, The Netherlands. Neuromuscul Disord. 2005;15:802-816.
25.
Campbell SK, Kolobe TH, Osten ET, Lenke M., Girolami GLConstruct validity of the test of infant motor performance. Phys Ther. 1995;75:585-596.
26.
Campbell SK, Hedeker D.Validity of the Test of Infant Motor Performance for discriminating among infants with varying risk for poor motor outcome. J Pediatr . 2001;139:546-551.
27.
Campbell SK, Kolobe TH, Wright BD, Linacre JMValidity of the Test of Infant Motor Performance for prediction of 6-, 9-and 12-month scores on the Alberta Infant Motor Scale. Dev Med Child Neurol. 2002;44:263-272.
28.
Lekskulchai R., Cole J.Effect of a developmental program on motor performance in infants born preterm. Aust J Physiother . 2001;47:169-176.
29.
Finkel RS, Hynan LS, Glanzman AM, et al. The test of infant motor performance: reliability in spinal muscular atrophy typeI. Pediatr Phys Ther. 2008;20:242-246.
30.
Finkel RS GA, Main M., Bertini E., Mercuri E.The CHOP INTEND: a reliable motor scale for infants with neuromuscular disease. Neuromuscul Disord. 2006;16:668.
31.
Werdnig G.Zwei frühinfantile hereditäre Fälle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. Arch Psychiatrie Nervenkrankheiten. 1891; 22:437-480.
32.
Hoffmann J.Über chronische spinale Muskelatrophie im Kindesalter, auf familiärer Basis. Deutsche Z Nervenheilkunde. 1893;3:427.
33.
Kugelberg E. , Welander L.Heredofamilial juvenile muscular atrophy simulating muscular dystrophy. AMA Arch Neurol Psychiatry . 1956;75:500-509.
34.
Wang HY, Yang YH, Jong YJEvaluation of muscle strength in patients with spinal muscular atrophy. Kaohsiung J Med Sci. 2002;18:241-247.
35.
de Visser M. , Verbeeten B. Jr.Computed tomography of the skeletal musculature in Becker-type muscular dystrophy and benign infantile spinal muscular atrophy . Muscle Nerve. 1985 ;8:435-444.
36.
Merlini L., Mazzone ES, Solari A., Morandi L.Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve. 2002;26:64-70.
37.
Wang CH, So YT, Chen X., et al. Hydroxyurea clinical trial in types II/III SMA Patients. 12th Annual International Spinal Muscular Atrophy Research Group Meeting (FSMA), Boston, MA; 2008.
38.
Mercuri E., Bertini E., Messina S., et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord. 2004;14: 130-135.
39.
Mercuri E., Bertini E., Messina S., et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology. 2007 ;68:51-55.
40.
Pane M., Staccioli S., Messina S., et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord. 2008;18: 536-540.
41.
Swoboda KJ, Scott C., Ascadi G., et al. SMA CARNI-VAL TRIAL: randomized double-blind placebo-controlled trial of L-carnitine and valproic acid in children wiht SMA type II. Families of SMA Annual Meeting, Boston, June 19-22, 2008, page 17; 2008.
42.
Miller RG, Moore DH, Dronsky V., et al, and the SMA Study Group.A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci. 2001;191:127-131.
43.
Kinali M., Mercuri E., Main M., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002;59:609-610.
44.
Merlini L., Solari A., Vita G., et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. 2003;18:537-541.
45.
Russell DJ, Rosenbaum PL, Cadman DT, Gowland C., Hardy S., Jarvis S.The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989;31: 341-352.
46.
Palisano RJ , Hanna SE, Rosenbaum PL, et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther. 2000;80:974-985.
47.
Rosenbaum PL , Walter SD, Hanna SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves . JAMA. 2002;288:1357-1363.
48.
Nelson L., Owens H., Hynan LS, Iannaccone STThe gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord. 2006;16:374-380.
Iannaccone ST, Hynan LSReliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol. 2003 ;60: 1130-1136.
51.
Iannaccone ST, Smith SA, Simard LRSpinal muscular atrophy . Curr Neurol Neurosci Rep. 2004;4:74-80.
52.
Wang CH, Lunn MRSpinal muscular atrophy: advances in research and consensus on care of patients . Curr Treat Options Neurol. 2008;10:420-428.
53.
Russell DJ, Leung KM, Rosenbaum PLAccessibility and perceived clinical utility of the GMFM-66: evaluating therapists' judgements of a computer-based scoring program. Phys Occup Ther Pediatr. 2003;23:45-58.
54.
Main M., Kairon H., Mercuri E., Muntoni F.The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation . Eur J Paediatr Neurol. 2003;7:155-159.
55.
Mercuri E., Messina S., Battini R., et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord . 2006;16:93-98.
56.
Tiziano FD, Bertini E., Messina S., et al. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul Disord. 2007;17:400-403.
57.
Krosschell KJ, Maczulski JA, Crawford TO, Scott C., Swoboda KJA modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord. 2006;16:417-426.
58.
Krosschell KJ , Scott C., Ascadi G., et al. Reliability of the Modified Hammersmith Function Motor Scale for SMA (MHFMS) in a multicenter trial of L-carnitine and valproic acid in children with SMA. 12th Annual International Spinal Muscular Atrophy Research Group Meeting, June 19-22, 2008; 2008.
59.
O'Hagen J.M. , Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients . Neuromuscul Disord. 2007;17:693-697.
60.
Glanzman AM, O'Hagen JM, McDermott MP, et al. Validation of the expanded Hammersmith Functional Motor Scale in SMA type II and III. 12th Annual International Spinal Muscular Atrophy Research Group Meeting, June 19-22, 2008; 2008.
61.
Berard C., Payan C., Hodgkinson I., Fermanian J.A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15:463-470.
62.
Berard C., Payan C., Fermanian J., Girardot F.A motor function measurement scale for neuromuscular diseases - description and validation study. Rev Neurol (Paris ). 2006;162:485-493.
63.
Msall ME, DiGaudio K., Duffy LC, LaForest S., Braun S., Granger CVWeeFIM.Normative sample of an instrument for tracking functional independence in children. Clin Pediatr (Phila). 1994;33:431-438.
64.
Leonard S., Msall M., Bower C., Tremont M., Leonard H.Functional status of school-aged children with Down syndrome. J Paediatr Child Health. 2002;38:160-165.
65.
Chung BH, Wong VC, Ip P.Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004;114:e548-e553.
66.
The Amyotrophic Lateral Sclerosis Functional Rating Scale.Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996;53:141-147.
67.
van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RARating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale. Mov Disord. 1994;9:84-88.
68.
Kaufmann P. , Levy G., Montes J., et al, and the QALS Study Group.Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8:42-46.
69.
Scelsa SN, MacGowan DJ, Mitsumoto H., et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology. 2005;64:1298-1300.
70.
Gordon PH, Moore DH, Miller RG, et al, and the Western ALS Study Group.Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045-1053.
71.
Steffensen B., Hyde S., Lyager S., Mattsson E.Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int. 2001;6:119-134.
72.
Steffensen BF, Lyager S., Werge B., Rahbek J., Mattsson E.Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol. 2002;44:623-632.
73.
Miller RG, Moore DH 2nd, Gelinas DF, et al, and the Western ALS Study Group.Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56: 843-848.
74.
A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (phase III). Neurology. 1999;52: 1427-1433.
75.
A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis.ALS CNTF Treatment Study Group. Neurology. 1996;46:1244-1249.
76.
Great Lakes Als Study Group . A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology. 2003;61:1503-1507.
77.
Escolar DM, Henricson EK, Mayhew J., et al. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve. 2001;24:787-793.
78.
Russman BS, Iannacone ST, Buncher CR, et al. Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema. J Child Neurol. 1992 ;7:347-353.
79.
Iannaccone ST, Russman BS, Browne RH, Buncher CR, White M., Samaha FJProspective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group . J Child Neurol. 2000;15:97-101.
80.
Merlini L., Bertini E., Minetti C., et al. Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve. 2004;29:548-552.
81.
Iannaccone ST, White M., Browne R., Russman B., Buncher R., Samaha FJMuscle fatigue in spinal muscular atrophy . J Child Neurol. 1997;12:321-326.
82.
Montes J., Cheng B., Diamond B., Doorish C., Mitsumoto H., Gordon PHThe Timed Up and Go test: predicting falls in ALS. Amyotroph Lateral Scler. 2007;8:292-295.
83.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166: 111-117.
84.
Solway S., Brooks D., Lacasse Y., Thomas S.A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest. 2001; 119:256-270.
85.
Garber CE, Friedman JHEffects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology. 2003;60:1119-1124.
86.
Yang YR, Wang RY, Lin KH, Chu MY, Chan RCTask-oriented progressive resistance strength training improves muscle strength and functional performance in individuals with stroke. Clin Rehabil. 2006;20:860-870.
87.
Mehrholz J. , Rutte K., Pohl M.Jump training is feasible for nearly ambulatory patients after stroke. Clin Rehabil . 2006;20: 406-412.
88.
Andersson C. , Asztalos L., Mattsson E.Six-minute walk test in adults with cerebral palsy. A study of reliability. Clin Rehabil. 2006;20:488-495.
89.
Takeuchi Y. , Katsuno M., Banno H., et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy . Muscle Nerve. 2008;38:964-971.
90.
Dibble LE, Lange M.Predicting falls in individuals with Parkinson disease: a reconsideration of clinical balance measures. J Neurol Phys Ther. 2006;30:60-67.
91.
Thurman DJ, Stevens JA, Rao JKPractice parameter: assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology . 2008;70:473-479.
92.
van Hedel HJ , Wirz M., Dietz V.Assessing walking ability in subjects with spinal cord injury: validity and reliability of 3 walking tests. Arch Phys Med Rehabil. 2005;86:190-196.
93.
van Hedel HJ , Wirz M., Curt A.Improving walking assessment in subjects with an incomplete spinal cord injury: responsiveness. Spinal Cord . 2006;44:352-356.
94.
Skura CL, Fowler EG, Wetzel GT, Graves M., Spencer MJAlbuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008 ;70:137-143.
95.
Finder JD, Birnkrant D., Carl J., et al, for the American Thoracic Society.Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004 ;170:456-465.
96.
Manzur AY, Muntoni F., Simonds A.Muscular dystrophy campaign sponsored workshop: recommendation for respiratory care of children with spinal muscular atrophy type II and III . 13th February 2002, London, UK. Neuromuscul Disord. 2003;13:184-189.
97.
Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999;52:1311-1323.
98.
Samaha FJ, Buncher CR, Russman BS, et al. Pulmonary function in spinal muscular atrophy. J Child Neurol. 1994;9:326-329.
99.
Souchon F., Simard LR, Lebrun S., Rochette C., Lambert J., Vanasse M.Clinical and genetic study of chronic (types II and III) childhood onset spinal muscular atrophy. Neuromuscul Disord. 1996 ;6:419-424.
100.
Kaufmann P. , Finkel R., Darras B., et al. The natural history of spinal muscular atrophy-preliminary results from the PNCR Network . Neuromuscular Disorders. 2007;17:776-777.
101.
Lyager S., Steffensen B., Juhl B.Indicators of need for mechanical ventilation in Duchenne muscular dystrophy and spinal muscular atrophy. Chest. 1995;108:779-785.
102.
Gilgoff IS , Kahlstrom E., MacLaughlin E., Keens TGLong-term ventilatory support in spinal muscular atrophy. J Pediatr. 1989;115:904-909.
103.
Stefanutti D., Fitting JWSniff nasal inspiratory pressure. Reference values in Caucasian children. Am J Respir Crit Care Med. 1999;159:107-111.
104.
Stefanutti D., Benoist MR, Scheinmann P., Chaussain M., Fitting JWUsefulness of sniff nasal pressure in patients with neuromuscular or skeletal disorders . Am J Respir Crit Care Med. 2000;162(4 pt 1):1507-1511.
Bach JR, Goncalves MR, Páez S., Winck JC, Leitão S., Abreu P.Expiratory flow maneuvers in patients with neuromuscular diseases . Am J Phys Med Rehabil. 2006;85:105-111.
107.
Man WD , Kyroussis D., Fleming TA, et al. Cough gastric pressure and maximum expiratory mouth pressure in humans. Am J Respir Crit Care Med. 2003;168:714-717.
108.
Mills GH, Kyroussis D., Hamnegard CH, Wragg S., Moxham J., Green M.Unilateral magnetic stimulation of the phrenic nerve. Thorax . 1995;50:1162-1172.
109.
Mills GH, Kyroussis D., Hamnegard CH, Polkey MI, Green M., Moxham J.Bilateral magnetic stimulation of the phrenic nerves from an anterolateral approach. Am J Respir Crit Care Med. 1996;154(4 pt 1):1099-1105.
110.
Nicot F., Hart N., Forin V., et al. Respiratory muscle testing: a valuable tool for children with neuromuscular disorders. Am J Respir Crit Care Med. 2006;174:67-74.
111.
Fauroux B. , Aubertin G., Clément A., Lofaso F., Bonora M.Which tests may predict the need for noninvasive ventilation in children with neuromuscular disease? Respir Med. 2008 [Epub ahead of print].
112.
Toussaint M., Steens M., Soudon P.Lung function accurately predicts hypercapnia in patients with Duchenne muscular dystrophy. Chest. 2007;131:368-375.
113.
Kaufmann P. , Muntoni F.Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design . Neuromuscul Disord. 2007;17:499-505.
114.
Feldman AB , Haley SM, Coryell J.Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther. 1990;70:602-610.
115.
Berg M., Jahnsen R., Froslie KF, Hussain A.Reliability of the Pediatric Evaluation of Disability Inventory (PEDI) . Phys Occup Ther Pediatr. 2004;24:61-77.
116.
Stein RE, Jessop DJThe impact on family scale revisited: further psychometric data. J Dev Behav Pediatr. 2003;24:9-16.
117.
Williams AR , Piamjariyakul U., Williams PD, Bruggeman SK, Cabanela RLValidity of the revised Impact on Family (IOF) scale. J Pediatr. 2006;149:257-261.
118.
Bach JR, Vega J., Majors J., Friedman A.Spinal muscular atrophy type 1 quality of life. Am J Phys Med Rehabil. 2003;82: 137-142.
119.
Chio A., Gauthier A., Calvo A., Ghiglione P., Mutani R.Caregiver burden and patients' perception of being a burden in ALS . Neurology. 2005;64:1780-1782.
120.
Chio A., Gauthier A., Vignola A., et al. Caregiver time use in ALS. Neurology. 2006;67:902-904.
121.
Varni JW, Seid M., Rode CAThe PedsQL: measurement model for the pediatric quality of life inventory . Med Care. 1999;37:126-139.
122.
Varni JW, Seid M., Kurtin PS PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations . Med Care. 2001;39:800-812.
123.
Hirtz D., Iannaccone S., Heemskerk J., Gwinn-Hardy K., Moxley R. 3rd, Rowland LPChallenges and opportunities in clinical trials for spinal muscular atrophy . Neurology. 2005; 65:1352-1357.
124.
Heemskerk J. , McCall J., Barnes K., et al. Chemical optimization of indoprofen for the treatment of SMA . 11th Annual International Spinal Muscular Atrophy Reserach Group Meeting, Schaumburg, IL, June 21-23, 2007; 2007.
125.
Bromberg MB , Swoboda KJMotor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve. 2002;25:445-447.
126.
Swoboda KJ , Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57:704-712.
127.
Mercuri E. , Pichiecchio A., Allsop J., Messina S., Pane M., Muntoni F.Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging. 2007; 25:433-440.
128.
Mercuri E. , Messina S., Kinali M., et al. Congenital form of spinal muscular atrophy predominantly affecting the lower limbs: a clinical and muscle MRI study. Neuromuscul Disord. 2004;14:125-129.
129.
Ueno T., Yoshioka H., Iwasaki N., Tanaka R., Saida Y.MR findings of spinal muscular atrophy Type II: sibling cases. Magn Reson Med Sci. 2003;2:195-198.
